Corporate Medical Policy

Venous Thrombosis Risk Testing AHS – M2041

**Definitions**

Venous thromboembolism (VTE) refers to a clot present in a blood vessel. The most common presentations of VTE are deep vein thrombosis (DVT) and pulmonary embolism (PE) (Bartholomew 2017).

Thrombophilia refer to hereditary and/or acquired abnormalities of hemostasis that predispose patients to thrombosis (Stevens et al., 2016).

**Related Policies**

Cardiovascular Disease Risk Assessment AHS –G2050
Genetic Testing for Lipoprotein A Variant(s) as a Decision Aid for Aspirin Treatment and/or CVD Risk Assessment AHS- M2082

***Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician.***

**Policy**

BCBSNC will provide coverage for venous thrombosis risk testing when it is determined the medical criteria or reimbursement guidelines below are met.

**Benefits Application**

This medical policy relates only to the services or supplies described herein. Please refer to the Member's Benefit Booklet for availability of benefits. Member's benefits may vary according to benefit design; therefore, member benefit language should be reviewed before applying the terms of this medical policy.

**When Venous Thrombosis Risk Testing is covered**

1. Genetic testing for Factor V Leiden mutation and Prothrombin gene G20210A mutation is considered medically necessary in patients without recurrent VTE risk factors (for example, surgery, prolonged immobilization, collagen vascular disease, malignancy, certain hematologic disorders) in any of the following situations:
   a. Age <50, any venous thrombosis
   b. Venous thrombosis in unusual sites (such as hepatic, mesenteric, and cerebral veins)
   c. Recurrent venous thrombosis
   d. Venous thrombosis and a strong family history of thrombotic disease
   e. Venous thrombosis in pregnant women or in women taking oral contraceptives
Venous Thrombosis Risk Testing AHS – M2041

2. Reimbursement for testing for protein C deficiency, protein S deficiency and antithrombin III deficiency is allowed in patients without recurrent VTE risk factors (for example, surgery, prolonged immobilization, collagen vascular disease, malignancy, certain hematologic disorders) in any of the following situations. Testing should be performed at least six weeks after acute thrombotic event and while the patient is not taking anticoagulants
   a. Age <50, any venous thrombosis
   b. Venous thrombosis in unusual sites (such as hepatic, mesenteric, and cerebral veins)
   c. Recurrent venous thrombosis
   d. Venous thrombosis and a strong family history of thrombotic disease
   e. Venous thrombosis in pregnant women or in women taking oral contraceptives
   f. Relatives of individuals with venous thrombosis under age 50
   g. Myocardial infarction in female smokers under age 50
   h. Before administration of oral contraceptives, targeted testing of women with a personal or family history of venous thrombosis
   i. Individuals with warfarin induced skin necrosis
   j. Infants who develop Neonatal Purpura Fulminans

When Venous Thrombosis Risk Testing is not covered

1. Reimbursement is not allowed for MTHFR genetic testing for hypercoagulable evaluation or for “at risk” family members.

2. Genetic Testing for inherited thrombophilia is considered investigational for the following situations:
   a. Evaluation of recurrent fetal loss, placental abruption, preeclampsia, or fetal growth restriction
   b. Evaluation of arterial thrombosis not attributable to paradoxical emboli
   c. Routine screening in the general population
   d. Routine screening of asymptomatic women considering oral contraceptive use or hormone replacement therapy
   e. Routine screening of asymptomatic pregnant women
   f. Prenatal or preimplantation testing
   g. Routine newborn screening

Testing for other factors, including the factor V HR2 variant, or prothrombin G1199A variant, or factor VII R353Q variant, or factor 13B V34L variant or PAI-1, as well as multi-gene panel testing is considered investigational.

Policy Guidelines

Background
A thrombus is “an aggregate of coagulated blood within the vascular system or heart which contains platelet, fibrin, leukocytes, and red blood cells in varying amounts” (Herrmann, 2018). This aggregate of blood can be problematic as it can obstruct normal blood circulation throughout the body and even travel to peripheral areas. The primary manifestations of venous
Venous Thrombosis Risk Testing AHS – M2041

Thromboembolisms (VTE) are deep vein thrombosis and pulmonary embolism. These conditions affect an estimated one million individuals in the United States annually (Bartholomew, 2017).

Thrombosis is widely theorized to develop due to Virchow’s Triad, which consists of abnormalities in blood flow, a vascular endothelial injury, and alterations in the blood constituents. Changes in any of these characteristics may cause the clot to form (Bauer & Lip, 2018). For example, sickle red blood cells may cause increased clumping or decreased adhesion to the vessel walls (Byrnes & Wolberg, 2017).

A deep vein thrombosis (DVT) refers to a thrombus in a “deep” vein whereas a pulmonary embolism (PE) refers to an obstruction of the pulmonary artery (or one of its branches) by foreign material (Kearon, 2018; Thompson, 2018). DVT of the lower extremities may cause symptoms, such as swelling or edema in the lower extremities, pain, and warmth in the affected area (Kearon, 2018). This thrombus may travel to the lungs (becoming an embolus) and cause a PE. A PE has similar symptoms to DVT but may include pulmonary issues, such as shortness of breath. The risk factors for VTE, PE, and DVT are similar (Thompson, 2018).

The two primary categories of risk factors for VTE are hereditary and acquired, and the genetic tendency toward VTE is referred to as inherited thrombophilia. Hereditary risk factors include genetic mutations such as Factor V Leiden mutations. The five most common genetic risk factors for VTE are Factor V Leiden mutations, prothrombin mutations, protein S defect, protein C defect, and antithrombin defect (Bauer & Lip, 2018). Approximately 50–60% of the variance in VTE incidence are attributed to genetic effects (Crous-Bou, Harrington, & Kabrhel, 2016).

Factor V Leiden (FVL) mutations cause coagulation factor V to be unresponsive to activated protein C. A single nucleotide change (G1691A) results in a point mutation of glutamine to arginine at position 506. 99% of carriers of this mutation are heterozygous, and only 5% of these heterozygotes will experience a VTE in their lifetime. These mutations are often suspected in patients experiencing a VTE at a young age (under 50), a VTE in unusual areas such as a portal vein, or recurrent VTEs (Bauer, 2018a). Protein C may also be genetically deficient, but this mutation is only seen in 2-5% of individuals with a VTE (Kearon, 2018). Protein S, a cofactor for the activated protein C control mechanism, and deficiencies in the protein may also confer additional risk for VTE (Bauer, 2017).

The second most common inherited thrombophilia is the G20210A mutation of prothrombin. This mutation is a gain of function mutation where clotting activity is increased by creating more thrombin and fibrin. The overall prevalence of this mutation is about 2% (Bauer, 2018c). Genetic defects of antithrombin (an inhibitor of thrombin) may also occur, but the estimated prevalence of antithrombin defects is only a maximum of 0.2% (Bauer, 2018b).

Acquired risk factors or predisposing conditions for thrombosis include a prior thrombotic event, recent major surgery, presence of a central venous catheter, trauma, immobilization, malignancy, pregnancy, the use of oral contraceptives or heparin, myeloproliferative disorders, antiphospholipid syndrome (APS), and a number of other major medical illnesses (Bauer & Lip, 2018). Patients with acquired hypercoagulability have an increased risk of venous thrombosis, arterial thrombosis, or both; however, there is a low risk of recurrence, regardless of thrombophilia status (Connors, 2017).

Clinical Utility and Validity

Lee et al performed whole exome sequencing on 64 patients with VTE to assess the types of mutations of inherited thrombophilias. Of these 64 patients, 39 of them were found to have a pathogenic variant or variant of unknown significance (VUS). 8 were found to have a Factor V mutation (6 with FVL and, 2 with less common mutations), 2 were found to have a prothrombin G20210A mutation, 6 were found to have a protein S mutation, 2 were found to have a protein C mutation, and 3 were found to have an antithrombin mutation (Lee et al., 2017).
Segal et al reviewed the utility of FVL and prothrombin G20210A testing. The authors reviewed 124 articles and concluded that although genetic testing for these two risk factors is very accurate (valid), the clinical utility is lacking due to lack of evidence demonstrating improvement in clinical outcomes (Segal et al., 2009).

**Applicable Federal Regulations**

Many labs have developed specific tests that they must validate and perform in house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA ‘88). As an LDT, the U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use.

**Guidelines and Recommendations**

**American College of Medical Genetics and Genomics (ACMG, 2018)**

ACMG has released guidelines for laboratory testing of venous thromboembolism (VTE). This 2018 edition superseded the 2005 edition. The guidelines are as follows:

Test for factor V Leiden and factor II c.*97G>A (this mutation is also known as G20210A) is recommended in the following circumstance:

- A first unprovoked VTE, especially <50 years old
- VTE at unusual sites (such as hepatic portal, mesenteric, and cerebral veins)
- Recurrent VTE
- Personal history of VTE with (a) two or more family members with a history of VTE or (b) one first-degree relative with VTE at a young age
- Patients with low activated protein C (APC) resistance activity

Testing may be considered in following circumstances:

- Females under the age of 50 who smoke tobacco and have a history of acute myocardial infarction
- Siblings of individuals known to be homozygous for factor V Leiden or factor II c.*97G>A, because they have a 1 in 4 chance of being a homozygote
- Asymptomatic pregnant female or female contemplating pregnancy, with a first-degree relative with unprovoked VTE or VTE provoked by pregnancy or contraceptive use
- Pregnant female or female contemplating pregnancy or estrogen use who has a first-degree relative with a history of VTE and is a known carrier for factor V Leiden and/or factor II c.98*G>A variant
- Pregnant female or female contemplating pregnancy with a previous non-estrogen-related VTE or VTE provoked by a minor risk factor, because knowledge of the factor V Leiden or factor II c.*97G>A status may alter pregnancy related thrombophylaxis (Zhang et al., 2018).

ACMG does not support testing for MTHFR variants in thrombophilia assessment due to the lack of correlation with negative pregnancy outcomes (Hickey, Curry, & Toriello, 2013)

**American Society of Hematology (ASH)**

In 2018, ASH released their guidelines for management of venous thromboembolism, which included the following recommendations (Lim et al., 2018):
Venous Thrombosis Risk Testing AHS – M2041

- “Recommends using a strategy starting with D-dimer for excluding PE in a population with low prevalence/PTP (≤5%), followed by ventilation-perfusion (VQ) scan or computed tomography pulmonary angiography (CTPA) for patients requiring additional testing.”
- “Recommends against using a positive D-dimer alone to diagnose PE, and against additional testing following negative CTPA or normal VQ scan in a population with low prevalence/PTP (≤5%).”
- “Suggests using a strategy starting with D-dimer for excluding PE in a population with intermediate prevalence/PTP (~20%), followed by VQ scan or CTPA for patients requiring additional testing.”
- “Recommends against using a positive D-dimer alone to diagnose PE, and against additional testing following negative CTPA or normal VQ scan in a population with intermediate prevalence/PTP (~20%).”
- “Recommends against using a positive D-dimer alone to diagnose PE, and against using D-dimer as a subsequent test following a negative CT scan in a population with high prevalence/PTP (≥50%).”
- “Suggests using a strategy starting with D-dimer for excluding recurrent PE in a population with unlikely PTP.”
- “Recommends using a strategy starting with D-dimer for excluding DVT in a population with low prevalence/PTP (≤10%), followed by proximal lower extremity ultrasound or whole-leg ultrasound for patients requiring additional testing.”
- “Recommends against using a positive D-dimer alone to diagnose DVT, and against additional testing following negative proximal or whole-leg ultrasound in a population with low prevalence/PTP (≤10%).”
- “Recommends against using a positive D-dimer alone to diagnose DVT in a population with intermediate prevalence/PTP (~25%).”
- “Recommends against using a positive D-dimer alone to diagnose DVT in a population with high prevalence/PTP (≥50%).”
- “Suggests using a strategy starting with D-dimer for excluding recurrent DVT in a population with unlikely PTP.”
- “Suggests a strategy starting with D-dimer for excluding upper extremity DVT in a population with low prevalence/unlikely PTP (10%), followed by duplex ultrasound if D-dimer is positive.”
- “Recommends against using a positive D-dimer alone to diagnose upper extremity DVT in a population with low prevalence/unlikely PTP (10%).”
- “Suggests a strategy of either D-dimer followed by duplex ultrasound/serial duplex ultrasound, or duplex ultrasound/serial duplex ultrasound alone for assessing patients suspected of having upper extremity DVT in a population with high prevalence/likely PTP (40%).”
- “Recommends against using a positive D-dimer alone to diagnose upper extremity DVT in a population with high prevalence/likely PTP (40%) (Lim et al., 2018).”

Society for Vascular Medicine (SVM)

This society recommends against workup for clotting disorders for patients with DVT as treatment will not change based on any abnormalities (SVM, 2013).

The American College of Obstetricians and Gynecologists (ACOG, 2013) clinical management guidelines recommend that screening for inherited thrombophilia “may be considered in the following clinical settings:

1. “A personal history of venous thromboembolism that was associated with a non-recurrent risk factor
2. “A first degree relative (parent or sibling) with a history of high-risk thrombophilia.”
Venous Thrombosis Risk Testing AHS – M2041

ACOG does not recommend “testing for inherited thrombophilias in women who have experienced recurrent fetal loss or placental abruption … because it is unclear if anticoagulation reduces recurrence.” Additionally, ACOG does not support testing for inherited thrombophilia in women with a history of preeclampsia or fetal growth restriction.

ACOG recommends that screening for inherited thrombophilias should include testing for “factor V Leiden mutation; prothrombin G20210A mutation; and antithrombin, protein C, and protein S deficiencies.” Also, it is recommended that testing be performed “(after 6 weeks) from the thrombotic event and while the patient is not pregnant and not taking anticoagulation or hormonal therapy.”

EGAPP (Evaluation of Genomic Applications in Practice and Prevention)

“The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group found adequate evidence to recommend against routine testing for Factor V Leiden (FVL) and/or prothrombin 20210G>A (PT) in the following circumstances: (1) adults with idiopathic venous thromboembolism (VTE). In such cases, longer term secondary prophylaxis to avoid recurrence offers similar benefits to patients with and without one or more of these mutations. (2) Asymptomatic adult family members of patients with VTE and an FVL or PT mutation, for the purpose of considering primary prophylactic anticoagulation. Potential benefits are unlikely to exceed potential harms. The evidence was insufficient to determine whether FVL/PT testing might have clinical utility in some circumstances, such as for identifying FVL homozygosity among asymptomatic family members of adults with idiopathic VTE or counseling patients about the risks and benefits of antithrombotic therapy. The recommendations do not extend to patients with other risk factors for thrombosis, such as contraceptive use, as the evidence review that serves as the basis for the recommendations focused primarily on idiopathic VTE (EGAPP, 2011).”

American Society of Hematology (ASH, 2013) recommends against testing “for thrombophilia in adult patients with venous thromboembolism (VTE) occurring in the setting of major transient risk factors (surgery, trauma or prolonged immobility)” (ASH, 2013).

The Anticoagulation Forum published guidance in the Journal of Thrombosis and Thrombolysis on (Stevens et al., 2016):

”Do not perform thrombophilia testing following an episode of provoked VTE.

- A positive thrombophilia evaluation is not a sufficient basis to offer extended anticoagulation following an episode of provoked VTE.”

”Do not perform thrombophilia testing in patients following an episode of unprovoked VTE.

- If a patient with unprovoked VTE and low bleeding risk is planning to stop anticoagulation, test for thrombophilia if test results would change this decision. A negative thrombophilia evaluation is not a sufficient basis to stop anticoagulants following an episode of unprovoked VTE in a patient with low bleeding risk and willingness to continue therapy. Heterozygosity for FVL or PGM does not increase the predicted risk of recurrence after unprovoked VTE to a clinically significant degree.”

”Do not test for thrombophilia in asymptomatic family members of patients with VTE or hereditary thrombophilia.

- As a family history of VTE confers an excess risk of thrombosis, relatives should be counseled regarding use of prophylaxis in high risk situations.”

“Do not test for thrombophilia in asymptomatic family members of patients with VTE or hereditary thrombophilia who are contemplating use of estrogen.
Venous Thrombosis Risk Testing AHS – M2041

- If a woman contemplating estrogen use has a first-degree relative with VTE and a known hereditary thrombophilia, test for that thrombophilia if the result would change the decision to use estrogen.”

“Do not perform thrombophilia testing at the time of VTE diagnosis or during the initial 3-month course of anticoagulant therapy. When testing for thrombophilias following VTE, use either a 2-stage testing approach or perform testing after a minimum of 3 months of anticoagulant therapy has been completed, and anticoagulants have been held.”

“Do not test for thrombophilia in asymptomatic family members of patients with VTE or hereditary thrombophilia who are contemplating pregnancy. If a woman contemplating pregnancy has a first-degree relative with VTE and a known hereditary thrombophilia… test for that thrombophilia if the result would change VTE prophylaxis decisions (Stevens et al., 2016).”

American College of Cardiology

Recent guidance published in the New England Journal of medicine by Gupta was summarized by Barnes for the American College of Cardiology:

1. “Venous thromboembolism (VTE) affects an estimated 300,000-600,000 patients annually in the United States.
2. The risk of VTE recurrence is best predicted by whether the initial VTE episode was provoked or unprovoked, not the results of inherited thrombophilia testing.
3. Most patients with a provoked VTE have recently undergone surgery, immobility, trauma, or have a concurrent cancer diagnosis. Concurrent use of hormones (e.g., estrogen-containing contraceptive pills) is also frequently considered a provoking factor for VTE development.
4. For patients with a first provoked VTE event, guidelines recommend anticoagulation for only 3 months (not longer). Prolonged anticoagulation is associated with an increased risk of bleeding that outweighs the risk of VTE recurrence for these patients.
5. Patients with an unprovoked VTE (none of the provoking risk factors listed above) require longer anticoagulation due to a higher risk of recurrence that outweighs the risk of bleeding associated with long-term anticoagulation therapy.
6. Thrombophilia testing performed in the setting of an acute clot or ongoing anticoagulation therapy will often result in spurious results (usually false positive). For example, natural anticoagulants (e.g., protein C and S, antithrombin) are consumed during an acute thrombotic event and the levels can be reduced by ongoing anticoagulant therapy.
7. A recent study identified that up to 55% of Medicare patients with provoked VTE had undergone inappropriate thrombophilia testing, associated with significant cost to the healthcare system.
8. While thrombophilia testing rarely impacts management decisions about anticoagulation therapy, it may be beneficial for genetic testing purposes in patients presenting with a first unprovoked VTE at a young age (e.g., <45 years) or at an unusual site.
9. For patients with unprovoked VTE at a young age, VTE at an unusual site, arterial thrombosis, or pregnancy morbidity, testing for antiphospholipid antibodies, JAK2 mutation, and paroxysmal nocturnal hemoglobinuria may be beneficial.
10. There is no role for extensive cancer screening (e.g., computed tomography scanning) in patients with VTE. Only routine, age-appropriate cancer screening is recommended (Barnes, 2017).”
Venous Thrombosis Risk Testing AHS – M2041

**Billing/Coding/Physician Documentation Information**

This policy may apply to the following codes. Inclusion of a code in this section does not guarantee that it will be reimbursed. For further information on reimbursement guidelines, please see Administrative Policies on the Blue Cross Blue Shield of North Carolina web site at www.bcbsnc.com. They are listed in the Category Search on the Medical Policy search page.

*Applicable service codes: 81240, 81241, 81291, 81400, 81479, 85300, 85301, 85302, 85303, 85305, 85306, 85307*

BCBSNC may request medical records for determination of medical necessity. When medical records are requested, letters of support and/or explanation are often useful but are not sufficient documentation unless all specific information needed to make a medical necessity determination is included.

**Scientific Background and Reference Sources**


Venous Thrombosis Risk Testing AHS – M2041

update: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med, 20(12), 1489-1498. doi:10.1038/s41436-018-0322-

Policy Implementation/Update Information

<table>
<thead>
<tr>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/1/2019</td>
<td>New policy developed. BCBSNC will provide coverage for venous thrombosis risk testing when it is determined to be medically necessary because the criteria and guidelines have been met. Medical Director review 1/1/2019. (jd)</td>
</tr>
<tr>
<td>5/14/19</td>
<td>Reviewed by Avalon 1st Quarter 2019 CAB. Minor revision to Description section and “Related Policies” section added. When Not Covered section reformatted, no change to policy intent. Policy guidelines and references updated. Medical Director review 5/2019. (jd)</td>
</tr>
<tr>
<td>10/29/19</td>
<td>Wording in the Policy, When Covered, and/or Not Covered section(s) changed from Medical Necessity to Reimbursement language, where needed. (gm)</td>
</tr>
</tbody>
</table>

Medical policy is not an authorization, certification, explanation of benefits or a contract. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the group contract and subscriber certificate that is in effect at the time services are rendered. This document is solely provided for informational purposes only and is based on research of current medical literature and review of common medical practices in the treatment and diagnosis of disease. Medical practices and knowledge are constantly changing and BCBSNC reserves the right to review and revise its medical policies periodically.